Evidence map›Paper›PMID 35142292›Full record

ArticleEndocrinology, diabetes & metabolism case reports2022

A rare case of 46,XX gonadal dysgenesis, Mayer-Rokitansky-Kuster-Hauser syndrome, pituitary and thyroid hypoplasia.

Rediet Ambachew, Amare Gulilat, Tewodros Aberra, Zewdu Terefework, Wubalem Bedilu, Getahun Tarekegn, Ahmed Reja

Open access · goldAbstract read
In one paragraph

Article in Endocrinology, diabetes & metabolism case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rediet AmbachewDepartment of Endocrinology, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia.
Amare GulilatDepartment of Endocrinology, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia.
Tewodros AberraDepartment of Endocrinology, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia.
Zewdu TerefeworkMRC-ET Advanced Laboratory, Addis Ababa, Ethiopia.
Wubalem BediluDepartment of Radiology, St. Paul's Hospital Millenium Medical College, Addis Ababa, Ethiopia.
Getahun TarekegnDepartment of Endocrinology, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia.
Ahmed RejaDepartment of Endocrinology, Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia.
Addis Ababa University · ETSt. Paul's Hospital Millennium Medical College · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summaryMayer-Rokitansky-Kuster-Hauser syndrome is characterized by congenital absence or hypoplasia of the uterus and upper two-thirds of the vagina in both phenotypically and karyotypically normal females with functional ovaries, whereas gonadal dysgenesis is a primary ovarian defect in otherwise normal 46,XX females. An association between these two conditions is extremely rare. We report a 21-year-old female presented with primary amenorrhea and undeveloped secondary sexual characteristics. The karyotype was 46,XX and the hormonal profile revealed hypothyroidism and hypogonadotropic hypogonadism. Pelvic MRI showed class I Mullerian duct anomaly with ovarian dysgenesis. Ultrasound showed bilateral thyroid hypoplasia and brain MRI suggested anterior pituitary hypoplasia. Levothyroxine and hormone replacement therapy were started. LEARNING POINTS: The simultaneous presentation of 46,XX gonadal dysgenesis, Mayer-Rokitansky-Kuster-Hauser syndrome, hypothyroidism, and pituitary hypoplasia is a Possibility. Extensive evaluation should be made when a patient presents with one or more of these features. The diagnosis imposes a significant psychological burden on patients and adequate counseling should be provided. Hormone replacement therapy remains the only therapeutic option for the development of secondary sexual characteristics and the prevention of osteoporosis.

Identifiers

PMID35142292
PMCPMC8859947
OpenAlexW4211040058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.